By leveraging computational approaches, including molecular docking and dynamics simulations, this study seeks to evaluate the compound’s ability to selectively target both TNKS1 and CDK8, thereby inhibiting the critical signaling pathways that drive RCC progression. Here, CDK8 is linked to renal cell carcinoma.